|
|
||||||||
Vanderbilt Heart and Vascular Institute, Nashville, Tennessee
Accepted for publication January 28, 2008.
* Address correspondence to Dr Byrne, Vanderbilt University Medical Center, Department of Cardiac Surgery, 1215 21st Avenue South, Nashville, TN 37232-8802 (Email: john.byrne{at}vanderbilt.edu).
Presented at the Fifty-fourth Annual Meeting of the Southern Thoracic Surgical Association, Bonita Springs, FL, Nov 7–10, 2007.
| Abstract |
|---|
|
|
|---|
Methods: One hundred and ninety-five consecutive patients (103 male and 92 female), age 69 ± 8 years, underwent surgery between January 2006 and July 2007. Mean preoperative New York Heart Association function class was 2.2 ± 0.7. Thirty-five patients (18%) had an ejection fraction 0.35 or less. Cardiopulmonary bypass was instituted through femoral (176 of 195, 90%), axillary (18 of 195, 9%), or direct aortic (1 of 195, 0.5%) cannulation. Under cold fibrillatory arrest (mean temperature 28.2°C) without aortic cross-clamp, mitral valve repair (72 of 195, 37%), mitral valve replacement (117 of 195, 60%), or other (6 of 195, 3%) procedures were performed. Concomitant procedures included maze (45 of 195, 23%), patent foramen ovale closure (42 of 195, 22%) and tricuspid valve repair (16 of 195, 8%), or replacement (4 of 195, 2%).
Results: Thirty-day mortality was 3% (6 of 195). Duration of fibrillatory arrest, cardiopulmonary bypass, and "skin to skin" surgery were 88 ± 32, 118 ± 52, and 280 ± 78 minutes, respectively. Ten patients (5%) underwent reexploration for bleeding and 44% did not receive any blood transfusions. Six patients (3%) sustained a postoperative stroke, eight (4%) developed low cardiac output syndrome, and two (1%) developed renal failure requiring hemodialysis. Mean length of hospital stay was 7 ± 4.8 days.
Conclusions: This simplified technique of minimally invasive open heart surgery is safe and easily reproducible. Fibrillatory arrest without aortic cross-clamping, with coronary perfusion against an intact aortic valve, does not increase the risk of stroke or low cardiac output. It may be particularly useful in higher risk patients in whom sternotomy with aortic clamping is less desirable.
| Introduction |
|---|
|
|
|---|
The aforementioned techniques, however, require the application of port access endoaortic balloon clamp [12] or a transthoracic direct aortic cross-clamp (applied through intercostal spaces with video assistance) [6, 13] and a cardioplegia delivery system [14]. One senior author (MRP) began a program of minimally invasive heart surgery using the original "Heart Port" platform in 1998. Over time, it evolved to a more simple and cost-effective approach by avoidance of cross-clamping and cardioplegic myocardial arrest using a small (5 cm) right anterolateral incision. This approach to the mitral and tricuspid valves, as well as other heart procedures performed through the right and left atrium, such as closure of atrial septal defect or removal of tumors or foreign bodies, has been used at Vanderbilt since January 2006.
| Material and Methods |
|---|
|
|
|---|
One hundred eighty-nine mitral valve procedures were performed. Concomitant procedures included tricuspid valve surgery (n = 19), maze procedure (n = 45), and atrial septal defect or patent foramen ovale (PFO) closure (n = 42). In addition, six other nonmitral valve minimally invasive open-heart procedures were performed. No patients underwent concomitant coronary artery bypass surgery. Fourteen patients underwent planned "one-stop" concomitant percutaneous coronary intervention (immediately prior to the open surgery) in the hybrid catheterization lab-operating room. Among the 60 patients with concomitant coronary disease, 14 had critical lesions that required coronary intervention at the time of the surgery. Demographic data are listed in Table 1.
|
|
Because the incision is more lateral, the visualization of the mitral valve is excellent and minimal retraction of the heart is needed, avoiding aortic valve distortion. This minimizes aortic insufficiency, enabling a reasonably bloodless field. In the event of more significant aortic insufficiency, flows on CPB can be decreased for 1 to 2 minute intervals intermittently provided the systemic pressure does not fall below 30 mm Hg. Keeping the aortic pressure greater than 30 mm Hg keeps the aortic valve closed, and prevents air in the left ventricle from entering the ascending aorta. If aortic insufficiency is greater than 2+ this approach may be contraindicated.
Rewarming and cardioversion with the external Zoll pads (ZOLL Medical Corporation) were performed and patients were weaned off CPB. Post pump TEE was performed to confirm proper valve and ventricular function and to ensure complete removal of air. The arterial and venous cannulae were removed and the vessels were repaired. A chest tube was placed in the right pleural chest and a 9/9 Blake drain in the pericardial space. The thoracotomy was closed in a standard fashion.
Data Analysis
Data are presented as mean values ± standard deviation or percentage. The statistical data analysis was performed using the STATA (College Station, Texas) 9.0 software package for Windows.
| Results |
|---|
|
|
|---|
|
|
|
|
| Comment |
|---|
|
|
|---|
|
The common theme of previously reported minimally invasive heart surgery approaches is the need of aortic cross-clamping and a cardioplegia delivery system. The latter can be challenging because the advancement of a coronary sinus catheter for retrograde cardioplegia may not always be possible, and sometimes can lead to perforation of the coronary sinus [17]. Alternatively a new version of the aortic endovascular occluder, which provides for direct cannulation of the ascending aorta and antegrade perfusion, can obviate some problems seen in the early series of the Port access [5]. However, if the aortic endovascular occluder dislodges or does not achieve complete aortic occlusion, this can lead to poor myocardial protection or worse. The use of direct antegrade aortic cardioplegia also poses the risk of aortic dissection.
In order to simplify the technique and avoid aortic cross-clamping and cardioplegic ischemia, we have adopted cold fibrillatory arrest. The key principle for myocardial protection is to keep the heart completely decompressed by opening the left atrium immediately upon fibrillation. The left ventricle cannot be allowed to distend. Vacuum-assisted drainage also assists with heart decompression. The coronaries are perfused with oxygenated blood against an intact aortic valve. If the aortic valve is incompetent this technique may be contraindicated. Our low incidence of low cardiac output syndrome (4%), despite 18% (35 of 195) of our patients with an ejection fraction 0.35 or less, confirms that this method offers excellent myocardial protection. We believe this is because minimal retraction of the heart is needed because the surgeon can visualize the valve easily, thereby avoiding aortic valve distortion, aortic insufficiency, and coronary malperfusion. Most prior studies on fibrillatory arrest have evaluated intermittent cross-clamp for coronary artery bypass grafting [18] and some [19] have reported an increase in myocardial acidosis when hypothermic fibrillatory arrest was used in emergent coronary revascularization. Our technique is different in that the myocardium never becomes ischemic and it is always decompressed.
Satisfactory removal of air in minimally invasive procedures may be difficult due to the limited access to the aorta or the apex of the heart [20]. Mohr and colleagues [21], in their series of Port access minimally invasive mitral valve surgery, have reported a higher rate of incomplete removal of air of the heart by transthoracic echo and a 17% rate of postoperative confusion. Grossi and colleagues [4] have used a right thoracotomy approach combined with endoaortic balloon occlusion and either peripheral or central cannulation, and in a large series of patients (714) reported 2.9% incidence of stroke. With the same approach Dogan and colleagues [5] have reported a 5% rate of transient ischemic attack, while Nifong and colleagues [22], in a large multicenter trial of robotic mitral valve surgery, have reported no stroke. Greelish and colleagues [3], using the lower hemisternotomy approach for mitral valve repair, have reported a 1.9% incidence of stroke. In a recent series from Svensson and colleagues [23], comparing the results of mitral valve reoperations done either through a redo-sternotomy versus a right thoracotomy approach, the incidence of stroke was 2.7% versus 7.5%, p = 0.04, respectively. In the right thoracotomy approach fibrillatory arrest was used in the majority of the patients (91%). Removal of air of the cardiac cavities was performed by the aortic root vent and a vent placed through the mitral valve. In our experience we had 3% stroke rate (none in the redo group). We attribute our low stroke rate to our adhering to four absolute precautions to decrease the risk of stroke: (1) the arterial perfusion pressure should never be allowed to go below 30 mm Hg (this keeps the aortic valve closed and prevents air from entering the ascending aorta); (2) in mitral valve repair, we do not test the repair by insufflating the left ventricle with a syringe of normal saline because this can push air or debris into the ventricle and aorta, but rather make the aortic valve incompetent to fill the left ventricle retrograde; (3) the use of carbon dioxide insufflation has markedly reduced the amount of air in the heart chambers and the air emboli; we flush carbon dioxide into the thoracic cavity at 5 liters per minute throughout the operation to prevent air; and finally (4) before the patient is cardioverted, we check for air by TEE; however, sometimes the patient converts on his own; the key aspect is to keep the mitral valve incompetent in order to avoid air emboli. In the case of valve replacement, we place a flexible pediatric vent or Foley catheter through the valve to keep it incompetent.
Contraindications to perform this approach are the presence of 2+ or greater aortic regurgitation because it limits the visibility of the surgical field, and causes coronary malperfusion; and the presence of pectus excavatum because of the difficulty of left atrial exposure due to the pushing of the sternum on the cardiac chambers. The presence of concomitant coronary artery disease has been a classic contraindication for minimally invasive valve surgery. Because these approaches offer significant improvement in outcomes, the use of simultaneous percutaneous coronary intervention was used in 7% of the patients in our hybrid cath lab-operating room. The tradeoff is an increased amount of bleeding resulting from antiplatelet agents [24]. In our experience only one patient in this group required reoperation for bleeding.
Mitral valve repair was successful in 66% of myxomatous valves. The majority (90%) of MVRs for myxomatous diseases occurred when patients had complex bileaflet disease. Thus, bileaflet repair is challenging whether using conventional or minimally invasive approaches. For complex bileaflet disease, it is the preference of some surgeons to replace the mitral valve rather than performing complex mitral valve repair. Ischemic valves were replaced 88% of the time and this followed surgeon preference. Recent evidence suggests that ischemic patients fare just as well with MVR as with repair, and repair is often not durable [25]. Because ischemic mitral regurgitation is largely a ventricular problem, some surgeons feel that MVR is preferable so as to assure valve competence considering most patients with ischemic mitral regurgitation will not outlive a biologic MVR.
Limitations
This was an uncontrolled series and data were retrospectively collected. The surgical approach was determined by surgeon's preference. Later during the study, however, this has become our standard approach for mitral and tricuspid valve surgery if no concomitant aortic valve disease is present. If complex bileaflet valve repair is deemed likely, a sternotomy may be preferable in some cases. Obviously, late follow-up will be needed to determine whether valve repairs are durable.
| Appendix |
|---|
Hospital mortality: death for any reason occurring within 30 days after surgery or after 30 days occurring during the same hospitalization.
Congestive heart failure: presence within two weeks prior to procedure of paroxysmal nocturnal dyspnea or dyspnea on exertion because of heart failure or chest X-ray showing pulmonary congestion.
Myocardial infarction (MI): acute if present
7 days from the last documented MI or evolving, if, at the time of surgery, Q-waves or ST changes were present along with a creatinine kinase-MB (CK-MB) > 5% of total CPK.
Urgent surgery: procedure required during the same hospitalization in order to minimize chance of further clinical deterioration, emergent if ischemic dysfunction (ongoing ischemia despite maximal medical treatment or IABP, acute/evolving MI, pulmonary edema requiring intubation) or shock.
Low cardiac output syndrome: was defined as a cardiac index
2.0 l/min/m2, requiring triple inotropic support to maintain a systolic pressure greater than 90 mm Hg for at least 30 minutes, or placement of an intraaortic balloon pump (IABP).
Perioperative myocardial infarction: appearance of new Q waves and a CPK MB fraction
100 IU/L.
Bleeding: necessity of reexploration of the thorax for suspected bleeding during the postoperative period.
Stroke: evidence in the postoperative period of a new central neurologic deficit persisting for >72 hours, while if the neurologic deficit resolved in 72 hours it was considered a transient ischemic attack.
Acute renal failure: an increase in creatinine to twice the preoperative value.
| Discussion |
|---|
|
|
|---|
I think the three technical challenges to overcome when you are doing this is, number one, how are you going to safely perfuse the patient, and my first question is, do you do anything besides just the TEE to select patients for safety of thermal perfusion? The second thing is how do you occlude the aorta and protect the heart? And you have chosen to deal with that by not dealing with it. And the third issue is, how do you actually operate on the valve pathology once you get there, what kind of instruments?
The second question that I would like to ask is, your repair rate overall was only about 35%, and I would like to just clarify, are you compromising your ability to repair the valve because of this procedure? If you did those patients through a sternotomy, do you think you would have a higher repair rate? Thank you very much.
DR GREELISH: Thank you for your comments and questions, Dr Smith. Issues regarding who can safely be perfused with this technique center primarily on two areas, first the degree of atherosclerosis in the aorta and second the degree of left ventricular hypertrophy. You need to exercise caution in those patients with a heavy plaque burden in the descending aorta and arch as assessed by TEE. In patients with significant disease you should avoid retrograde perfusion from the groin for fear of dislodging embolic material. In this situation the axillary artery should be selected. Regarding patients with significant left ventricular hypertrophy, I think you need to be aware of the vulnerability of the subendocardium and it's predilection for ischemia with low perfusion pressures with this technique. In these patients you have to keep the perfusion pressures high.
You are also correct in saying that we do not cross-clamp the aorta with our technique. It is always done under hypothermic fibrillatory arrest with high perfusion pressures to protect the heart. The techniques of repair or replacement are identical to the open technique, but as you have alluded to, special instruments are needed. We use Heartport-type graspers and needle drivers, and we have a custom handheld retractor as I have shown.
Regarding your second question about the distribution of mitral valve repair versus replacement in our series, overall there may be a slightly lower incidence of mitral valve repair than in some series. However, when you analyze the data, you see that the majority of the patients that underwent mitral valve replacement in the myxomatous category were those who had bileaflet disease. These patients are particularly challenging in most surgeons' hands and are associated with a much higher rate of failure if repair is attempted. In the ischemic group there was a tendency for more mitral valve replacements due surgeon preference issues and the current data on repair in this group. Dr Petracek who brought this procedure over from St. Thomas Hospital tends to perform more mitral valve replacements, especially in ischemics. This approach is now in vogue as we have learned that ischemic MR is really a ventricular problem rather than a valve problem and as data continues to come out that there is up to a 30% failure rate in ischemics undergoing mitral valve repair.
| Acknowledgments |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Atoui, B. Bittira, J. E. Morin, and R. Cecere On-pump beating heart mitral valve repair in patients with patent bypass grafts and severe ischemic cardiomyopathy Interactive CardioVascular and Thoracic Surgery, July 1, 2009; 9(1): 138 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. McClure, L. H. Cohn, E. Wiegerinck, G. S. Couper, S. F. Aranki, R. M. Bolman III, M. J. Davidson, and F. Y. Chen Early and late outcomes in minimally invasive mitral valve repair: an eleven-year experience in 707 patients. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 70 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Byrne, M. Leacche, D. E. Vaughan, and D. X. Zhao Hybrid Cardiovascular Procedures J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 459 - 468. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |